Dordrecht, Netherlands

Rémon Boer

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rémon Boer: Innovator in β-Lactam Antibiotics Production

Introduction

Rémon Boer is a notable inventor based in Dordrecht, Netherlands. He has made significant contributions to the field of antibiotic production, particularly in the development of β-lactam antibiotics. His innovative approach has led to advancements in the synthesis of these crucial pharmaceuticals.

Latest Patents

Rémon Boer holds a patent for the production of β-lactam antibiotics. The patent describes a process involving an IPNS-catalyzed conversion of precursor tripeptides, specifically hydroxyphenylglycyl-cysteinyl-valine (HpgCV) and phenylglycyl-cysteinyl-valine (PgCV). This process results in the formation of N-hydroxyphenylglycyl or N-phenylglycyl β-lactam antibiotics. The tripeptides can be synthesized by combining hydroxyphenylglycine (Hpg), phenylglycine (Pg), cysteine (C), and valine (V) using a non-ribosomal peptide synthetase (NRPS). The invention also includes an improved IPNS with enhanced activity for this conversion.

Career Highlights

Throughout his career, Rémon Boer has worked with prominent companies in the pharmaceutical industry. He has been associated with DSM IP Assets B.V. and Centrient Pharmaceuticals Netherlands B.V. These experiences have allowed him to apply his innovative ideas in practical settings, contributing to the advancement of antibiotic production.

Collaborations

Rémon Boer has collaborated with notable professionals in his field, including Marcus Hans and Roelof Ary Lans Bovenberg. These collaborations have fostered a productive environment for innovation and development in antibiotic research.

Conclusion

Rémon Boer is a distinguished inventor whose work in the production of β-lactam antibiotics has made a significant impact on the pharmaceutical industry. His innovative processes and collaborations continue to influence the field of antibiotic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…